In this section
@article{Leng:2025:10.1038/s41541-025-01159-0,
author = {Leng, T and Whittles, LK and Nikitin, D and White, PJ},
doi = {10.1038/s41541-025-01159-0},
journal = {npj Vaccines},
title = {Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness},
url = {http://dx.doi.org/10.1038/s41541-025-01159-0},
volume = {10},
year = {2025}
}
TY - JOUR
AB - Vaccination for UK men-who-have-sex-with-men (MSM) at increased gonorrhea risk has been advised, but not yet implemented. Effective targeting is essential for cost-effectiveness, but previously-examined approacheshave disadvantages: Vaccination-on-Diagnosis has low coverage (limiting impact), and Vaccination-according-to-Risk requires asking about sexual behavior to identify at-risk individuals, which is not always feasible. Wedeveloped a transmission-dynamic model to evaluate novel strategies offering vaccination based on information readily-available to clinicians (diagnostic/vaccination history, if the patient is seeking care due to partner notification). Offering vaccination to MSM who are notified partners of gonorrhea cases or were diagnosed themselves in the past 2 years averts 1.6x more cases and is more cost-effective than Vaccination-on-Diagnosis. If vaccination provides 20% protection for 1.5 years after primary vaccination and 3 years after revaccination then at £18/dose administered, all considered strategies have ≥ 50% and ≥ 90% probabilities of positive net monetary benefit compared with no vaccination with a quality-adjusted life year valued at £20,000 and £30,000 respectively, thus meeting the UK criteria for cost-effectiveness. All novel strategies considered achieve greater impact than Vaccination-on-Diagnosis without the feasibility issues of Vaccination-according-to-Risk.
AU - Leng,T
AU - Whittles,LK
AU - Nikitin,D
AU - White,PJ
DO - 10.1038/s41541-025-01159-0
PY - 2025///
SN - 2059-0105
TI - Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness
T2 - npj Vaccines
UR - http://dx.doi.org/10.1038/s41541-025-01159-0
UR - https://www.nature.com/articles/s41541-025-01159-0
VL - 10
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk